ArticleBMC ophthalmology2026
Long-term efficacy of combined phacoemulsification and Hydrus microstent in open-angle glaucoma versus combined-mechanism/primary angle closure glaucoma: a retrospective cohort study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCompare the efficacy of combined Hydrus-cataract surgery in open angle glaucoma (OAG) to combined mechanism glaucoma (CMG) and primary angle closure glaucoma (PACG) over 36 months.
methodsA retrospective cohort study of patients with CMG, PACG, or OAG who were treated with 1 or more glaucoma medications prior to surgery. Retrospective review of OAG, CMG, or PACG eyes which underwent combined Hydrus-cataract surgery between Jul 2020-Dec 2021. Regression models were used to evaluate IOP, medication use, success rate (IOP ≤ 18 mmHg without medication) and proportion of medication-free eyes.
resultsThe CMG/PACG group (n = 39) had significantly higher IOP reduction from baseline to 36-months than the OAG group (n = 34) (OAG, 15.03 ± 2.90 mmHg to 13.44 ± 3.85 mmHg, p = 0.016; CMG/PACG, 15.62 ± 3.10 to 13.21 ± 2.61 mmHg, p = 0.002) (p = 0.021 for difference). Number of medications was significantly reduced in both groups (OAG, 2.44 ± 1.33 to 1.18 ± 1.40, p < 0.001; CMG/PACG, 2.29 ± 1.27 to 0.87 ± 1.08, p < 0.001) (p = 0.882 for difference). CMG/PACG had higher success rate (49% vs. 29%) and more medication-free eyes (49% vs. 35%) than OAG but these were not statistically significant (p = 0.09 and 0.25, respectively).
conclusionsThis retrospective study supports the long-term efficacy of combined Hydrus-cataract surgery for CMG/PACG and OAG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.